Previous 10 | Next 10 |
Fresh IPO COMPASS Pathways ([[CMPS]] +12.0%) is up in early trade on increased volume. Demand has been robust since its September 18 debut. Shares are up almost 150% from its offering price of $17.Today, Citron Research published a bullish report with a $100 price target. Key points...
Similar to Cannabis, Mushrooms could be the next big investment craze. The current political climate favors psychedelics. Near term catalyst could help this become mainstream. For further details see: Macro Trends Making Mushrooms A Magical Investment
"They are the first ones using psilocybin, what’s in the magic mushrooms, for FDA approval for mental health purposes," Andrew Left tells Benzinga. "It's one of those big concept stocks."U.K.-based Compass Pathways (CMPS) came public two weeks ago, pricing its U.S. IPO at $17 per share...
Chatter around psilocybin was at a fever pitch early this year, as a growing choir of voices cheered the potential for the psychedelic component of “magic mushrooms” to treat a bevy of difficult diseases and conditions where traditional drugs have failed miserably. The roars o...
Gainers: Adial Pharmaceuticals (ADIL) +33%, Spero Therapeutics (SPRO) +16%, LogicBio Therapeutics (LOGC) +14%, AngioDynamics (ANGO) +14%, Windtree Therapeutics (WINT) +10%.Losers: Myovant Sciences (MYOV) -21%, TransMedics Group (TMDX...
Psilocybin could soon help millions of people tackle obesity and eating disorders. After all, the global obesity epidemic is still bursting at the seams. According to the World Health Organization (WHO) obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adul...
Shroom Stocks Take Center Stage After Latest IPO There’s a new breed of penny stocks you might’ve not heard of recently. It’s called psychedelic stocks. You might’ve also heard about shroom or mushroom stocks. But now we’ve got the next phase, pote...
September 24, 2020 (MicroSmallCap via Comtex) — Last year may have been all about cannabis, but it’s clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson’s (NYSE:JNJ) ketamine-derived medicine, Spravato, r...
Psychedelics, like psilocybin are going mainstream – and fast. Already, over the last few months, Denver, Oakland, and Santa Cruz have recently legalized its use. Joining them, Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms, as well. In addition, a ballot i...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 24, 2020 – Last year may have been all about cannabis, but it’s clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Joh...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...